Cargando…

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

Detalles Bibliográficos
Autores principales:	Yokota, S, Imagawa, T, Miyamae, T, Kasai, K, Mori, M, Nishimoto, N, Kishimoto, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334165/ http://dx.doi.org/10.1186/1546-0096-6-S1-S1

Ejemplares similares

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
por: Yokota, S, et al.
Publicado: (2003)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
por: Hinze, CH, et al.
Publicado: (2008)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Correlation between clinical indices and findings of joint ultrasonography in juvenile idiopathic arthritis with adalimumab therapy
por: Hara, Ryoki, et al.
Publicado: (2011)

Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
por: Mori, Masaaki, et al.
Publicado: (2008)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

PReS-FINAL-2177: Safety and lack of autoantibody production following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis (JIA)
por: Aikawa, N, et al.
Publicado: (2013)

Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
por: Zak, M, et al.
Publicado: (2008)

Regulatory T cells from the inflamed joints of patients with juvenile idiopathic arthritis (JIA) are dysregulated and display a pro-inflammatory profile
por: Pesenacker, AM, et al.
Publicado: (2011)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

Thalidomide: efficacy and side effects in juvenile idiopathic arthritis (JIA)
por: Alpigiani, MG, et al.
Publicado: (2008)

Juvenile idiopathic arthritis (JIA): can an integrated medicine be possible?
por: Officioso, A, et al.
Publicado: (2011)

Sport and exercise habits in children with juvenile idiopathic arthritis (JIA)
por: Nørgaard, M, et al.
Publicado: (2011)

Pregnancy outcomes in women affected by juvenile idiopathic arthritis (JIA)
por: Alpigiani, Maria Giannina, et al.
Publicado: (2014)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Sleep, fatigue and quality of life in juvenile idiopathic arthritis (JIA) and Juvenile Dermatomyositis (JDM)
por: Avie, Y Butbul, et al.
Publicado: (2008)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Replication of the association of the COG6 gene with juvenile idiopathic arthritis (JIA)
por: Hinks, A, et al.
Publicado: (2011)

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2011)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Efficacy of thalidomide for a girl with inflammatory calicinosis, a severe complication of juvenile dermatomyosistis
por: Miyamae, T, et al.
Publicado: (2008)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Psychological characteristics of the patients with juvenile idiopathic arthritis (JIA) of various age groups
por: Stepanenko, NY
Publicado: (2011)

Osteoblast differentiation from synovial fluid cells in juvenile idiopathic arthritis (JIA)
por: Jelusic-Drazic, Marija, et al.
Publicado: (2012)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Talus Arthritis Pattern in Juvenile Idiopathic Arthritis (JIA)
por: Alkhreisat, Mohammad, et al.
Publicado: (2019)

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model
por: Bracaglia, Claudia, et al.
Publicado: (2014)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iuvrfu07ami4ksavflb410imlo